Gan & Lee, Innovent, Xianyan, and Sinomab are all here! 2026BPD Chengdu Forum deconstructs the full-chain development of complex molecular drugs

Global biopharmaceutical innovation is enteringComplex moleculesEra.Peptide drugsEntering a golden era: more than 120 peptide drugs are now on the global market.Nucleic Acid DrugsContinuously advancing in areas such as extrahepatic delivery.ADC TrackRapid iteration with a global pipeline of 406 products in development and on the market.RadiopharmaceuticalsAchieve a new wave of original breakthroughs from 0 to 1, as the domestic 1-class innovative nuclear medicine receives approval for market launch.AIAccelerating the transformation of R&D paradigms. The next-generation competition in innovative drugs no longer hinges solely on molecular design, but also depends onDelivery Technology、CMC Process、Scaled Production & Global Compliancesystematic capabilities.

Against this backdrop, 2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityGrandly hosted, bringing together2000+Professional Buyers,70+Keynote Speakers,Innovative Complex Molecule Drug Development ForumAs a core track, we focus on complex modalities including peptides, nucleic acids, ADCs, and radiopharmaceuticals. Sessions will cover innovative R&D, CMC development, scale-up manufacturing, and commercialization strategies. We invite bioprocess professionals to explore new pathways for industrializing complex molecules and seize strategic opportunities in next-generation innovative drugs.

Forum Schedule & Highlights

Highlights Preview

• End-to-end topic orchestration: balancing innovation with practical implementation.
  The forum traces the journey of complex molecules from innovative R&D to commercialization, covering cutting-edge sectors such as peptides, nucleic acids, ADCs, and radiopharmaceuticals. It directly addresses practical industrial challenges including early-stage research, CMC, scale-up manufacturing, quality control, and global compliance.

• Leading figures from regulation, academia, industry, and craftsmanship gather together
  Regulatory experts and leaders from academic institutions such as the Chinese Academy of Sciences joined senior executives from leading companies including Gan & Lee Pharmaceuticals, Sun Pharma, Innovent Biologics, Sinolab Nuclear Medicine, and Federal Bio to discuss industrialization breakthroughs and commercialization pathways.

• Focus on the deep waters of industrialization, delivering outstanding practical value.

  Directly addressing top industry pain points in multipeptide scale-up, extrahepatic nucleic acid delivery, and radiopharmaceutical CMC. Delivers actionable insights through reports, interviews, and strategic dialogues.

Innovative Complex Molecule Drug Development Forum Agenda

Schedule updated through 9/28

Innovative R&D and Scalable Production of Peptide Drugs

Report: Natural Peptide Library & AI Discovery Platform

Guest: Liu Lulu, BD Director, PedBio

Report: Formulation Development Direction (Tentative)

Guest: Yang Fengyun, Director of Formulation Development at Gansu R&D Pharmaceutical

Report: CR059: Long-acting Efficacy Study of Circular RNA Encoding GLP-1 Analog

Guest: Peiya, Chief Director of Early Drug R&D at PegBio

Report: Engineering of Metabolic Peptides

Guest: Nie Yunyu, Chief Scientist of Metabolic Peptide Engineering at Innovent Biologics

Report: Peptide Drug Process Scale-Up and Manufacturing (Provisional)

Guest: ARI

Report: Super-Scale Production of GLP-1 Class Peptide Drugs (Provisional)

Guest: Liu Hedong, Senior Manager of Microbial Process Development Platform & Hengqin Early Development Platform, Federal Biotech

Interview: CMC and Industrialization of Peptide Drugs: Scale-up, Quality Control, and Global Compliance

Guest: Fan Jun, Vice President of CMC R&D Center, MacroCap

Innovative Development of Nucleic Acid Drugs and Extracellular Delivery Innovations

Report: Dual-Target siRNA Drug

Guest: Wan Jinqiao, Chairman of Xianyan Biomaterials

Report: From Identification to Delivery: Application of Nucleic Acid Aptamers in Extracellular Targeted Delivery

Guest: Luo Zhaofeng, Senior Engineer at the Hangzhou Institute of Medicine, Chinese Academy of Sciences; Deputy Director and Co-founder of the Nucleic Acid Aptamer Screening Center

Report: Novel Lipid Nanoparticle Nucleic Acid Delivery System

Guest: Li Jianguang, Haichang Biotech, CSO

Innovative Development of Complex Molecules

Report: Pending

Guest: Ye Junmin, Salubris, CSO

Report: Innovative ADC R&D (Tentative)

Guest: Zhenwei Miao, Chairman and CEO of Ake Rui Si & Ying Bai Rui

Report: Progress in KRAS Inhibitor Development

Guest: Li Yingfu, Founder & Chairman of Haibowei Pharmaceuticals

High-level Strategy

Interview: Industrial Breakthroughs and Commercialization Path Choices for Frontier Molecules

Guest: Chen Dianjun, President and CSO of Chengdu Xingrui Jingxuan Biotechnology

Bai Ge, Guotong New Drugs, COO

Wang Zheng, CEO of Sinotrac Nuclear Medicine

Xiahai Hong, Chief Scientist, SPIC Nuclide Innovation (Chongqing) Technology Co., Ltd.

Innovative R&D and CMC Development Strategies for Radiopharmaceuticals

Report: The Critical Role of Novel Metal Chelators in Radiopharmaceutical Development

Guest: Wang Zheng, CEO of Sinotrac Nuclear Medicine

Report: Alpha Nuclide R&D and Production Direction

Guest: Xia Haihong, Chief Scientist, SPIC Nuclear Isotope Innovation (Chongqing) Technology Co., Ltd.